Lizhinuo — Chelated Calcium, Winner of the Hubei Provincial Science and Technology Progress Award!

* Chelated Calcium, Winner of the Hubei Provincial Science and Technology Progress Award!

The Hubei Provincial Science and Technology Innovation Conference announced the list of winners of the 2021 Hubei Provincial Science and Technology Awards. Among them, Wuhan Ximo Pharmaceutical Co., Ltd. (hereinafter referred to as “Wuhan Ximo Pharmaceutical,” www.ximon.cn) received the Second Prize of the Hubei Provincial Science and Technology Progress Award for its project “Key Technological Innovation and Industrialization of Compound Calcium Carbonate Granules.” Wuhan Ximo Pharmaceutical was the only innovative pharmaceutical enterprise in Hubei Province to receive an award in 2021.

As emphasized by central leadership during an inspection tour in Wuhan, Hubei: “We must firmly grasp the lifeline of science and technology in our own hands, continuously enhancing China’s developmental independence, autonomy, and security”; and “Science and technology constitute the primary productive force; scientific and technological self-reliance and self-strengthening form the foundation of national prosperity and the cornerstone of national security.” Upholding its original mission, Wuhan Ximo Pharmaceutical remains committed to scientific and technological innovation and deeply implements the innovation-driven development strategy—firmly grasping the lifeline of science and technology in its own hands! Li Zhi Zhu® is the first product in China developed using Class 2.1 New Drug Technology (a novel pharmaceutical technology combining chelation and inclusion), representing a proprietary, third-generation calcium supplement—chelated calcium (NMPA Approval No.: H20173214). Li Zhi Zhu® establishes the world’s highest pharmaceutical standard for “Calcium + Vitamin D,” resolving the clinical challenges associated with poor digestion and absorption of calcium carbonate, as well as those related to vitamin D3 stability and uniformity. Its leading-edge technology not only comprehensively surpasses foreign products but also breaks multiple market monopolies held by overseas competitors. This project has achieved remarkable results both in terms of scientific and technological achievements and industrialization outcomes!

The elderly, children, and pregnant/postpartum women represent special clinical populations particularly susceptible to bone diseases caused by calcium deficiency. When taking conventional calcium supplements, these groups commonly experience low calcium absorption efficiency and poor clinical efficacy—“ingesting calcium without effectively supplementing it”—thereby adversely affecting bone health and quality of life. During reconstitution, Li Zhi Zhu® directly transforms water-insoluble calcium carbonate (“rock-like” calcium) into readily soluble calcium citrate chelate, thereby solving the clinical challenge of “poor solubility and difficult absorption” inherent to calcium carbonate. Published medical literature confirms that Li Zhi Zhu® significantly enhances calcium absorption rates, reduces gastrointestinal adverse reactions, lowers the risk of urinary calculi, and carries no contraindications for patients with kidney stones or gout. Since its market launch, Li Zhi Zhu® has rapidly gained adoption across more than 200 key hospitals nationwide, benefiting over 20 million calcium-deficient patients. Clinical studies and advantages of Li Zhi Zhu® (active ingredients: calcium citrate chelate + vitamin D3) have been widely published in professional medical journals and are highly regarded by clinical experts and widely accepted by patients. Adhering steadfastly to its strategic vision of “developing high-quality pharmaceuticals to support bone health,” Wuhan Ximo Pharmaceutical has consistently increased R&D investment over successive years.

As an innovative and dynamic enterprise, Wuhan Ximo Pharmaceutical has evolved into a high-tech enterprise and a “Little Giant” enterprise in science and technology, establishing strategic research collaborations with renowned institutions such as Huazhong University of Science and Technology. The receipt of this prestigious science and technology award signifies that Wuhan Ximo Pharmaceutical’s sustained R&D efforts have yielded tangible scientific outcomes and translated successfully into economic benefits—further validating the positive impact and effectiveness of its innovation-driven development strategy.